The reiteration of an Overweight rating and a high price target by a reputable analyst like Charles Duncan from Cantor Fitzgerald is likely to instill confidence among investors and could lead to a positive short-term impact on Jazz Pharmaceuticals' stock price. The $180 price target suggests a strong upside potential from current levels.